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Increasing evidence points to the importance of aberrant
O-glycosylated immunoglobulin A1 (IgA1) in the
pathogenesis of IgA nephropathy (IgAN), a disease widely
considered to be a polygenic disorder. We earlier found that
haplotypes in two key glycosyltransferase genes, C1GALT1
and ST6GALNAC2, were associated with susceptibility to IgAN.
Here we measured the genetic interaction of variants in
C1GALT1 and ST6GALNAC2 by applying FAMHAP software
to analyze haplotype–haplotype interaction in IgAN.
As confirmation, we also used a novel divergence-based
multi-locus algorithm (DBMA) approach to determine
interactions between single-nucleotide polymorphisms.
Haplotype–haplotype combinations in C1GALT1 and
ST6GALNAC2 were significantly associated with a
predisposition for IgAN and with the estimated glomerular
filtration rate (eGFR) of patients. Analogously, results from
DBMA found a five-locus combination, two in ST6GALNAC2
and three in C1GALT1, which was associated with IgAN
predisposition, eGFR, and renal outcome of patients with
IgAN. In addition, patients with a high risk had significantly
more exposed N-acetylgalactosamine on their IgA1 than did
patients with a lower risk of developing this disease. Our
findings suggest that potential genetic interactions of
C1GALT1 and ST6GALNAC2 variants influence IgA1
O-glycosylation, disease predisposition, and disease severity,
and may contribute to the polygenic nature of IgAN.
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Immunoglobulin A nephropathy (IgAN) is generally known
to be the most common primary glomerulonephritis.1
Genetic factors are considered to be involved in IgAN,
according to ethnic and geographical variations in prevalence
and to clinical manifestations,2 as well as to the worldwide
reported familial clustering of IgAN.3,4 In earlier decades, lots
of efforts were taken and significant progress has been
achieved in the genetic field of IgAN. In linkage analysis,
regions 6q22–23, 4q26–31, 17q12–22, and 2q36 were reported
to contribute to familial IgAN,5–7 although no specific
pathogenic gene was found in these regions until now. In
association studies, many progression-associated genes were
identified, such as selectin genes and renin–angiotensin
system-related genes,8–10 but little focus was given to the
specific genes relating to initial events in IgAN pathogenesis.
Thus, genetic studies based on a new approach and candidate
genes raised from pathogenic mechanisms of IgAN are
urgently required.
In recent years, increasing evidences from both in vivo and
in vitro studies implicated the importance of aberrant
glycosylated IgA1 in IgAN. In patients with IgAN, all
investigations, including our earlier studies, reported an
abnormal O-glycosylation of IgA1, with reduced galactose
and/or sialic acid, and associated with pathological pheno-
types.11–14 Recently, Gharavi et al.15 also reported the
inherited pattern of aberrant IgA1 glycosylation. Further-
more, we found that the aberrant sialylated serum IgA1 level
was associated with prognosis in IgAN patients.16 In vitro,
aberrant glycosylated IgA1 showed a higher binding capa-
city17,18 and a stronger biological effect on cultured human
mesangial cells.19–21
On the basis of the important roles of genetic factors and
aberrant glycosylated IgA1 in IgAN, we chose two key
glycosyltransferase genes, C1GALT1 (encoding core 1
synthase, glycoprotein-N-acetylgalactosamine 3-b-galactosyl-
transferase, 1; OMIM*610555) and ST6GALNAC2 (encoding
ST6 (a-N-acetyl-neuraminyl-2,3-b-galactosyl-1,3)-N-acetyl-
galactosaminide a-2,6-sialyltransferase-2; OMIM*610137) as
candidates, and carried out two case–control association
studies in a large Northern Chinese population. The two
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studies showed a protective haplotype, YATIG (odds ratio
(OR)¼ 0.70; frequency: control¼ 0.1168, case¼ 0.0719), and
two risky haplotypes, YAGDA (OR¼ 1.77; frequency: con-
trol¼ 0.0791, case¼ 0.1236) and YATDG (OR¼ 3.03; fre-
quency: control¼ 0.0298, case¼ 0.0840), in C1GALT1,22 and
a functional regulatory haplotype, ADG (OR¼ 1.36; fre-
quency: control¼ 0.1465, case¼ 0.1905), in the promoter
region of ST6GLANAC2,23 which implied that the variants in
C1GALT1 and ST6GALNAC2 were factors involved in the
genetic susceptibility to IgAN.
Recently, with the emerging concept that multiple genes
may interact in complex ways to induce the occurrence and
phenotypic variability of common complex diseases, some
achievements have been made in showing the genetic
pathogenesis of polygenic diseases, thanks to the multi-locus
approaches.24 For example, COMT, CYP1A1, and CYP1B1
were shown to jointly contribute to susceptibility to breast
cancer using multifactor-dimensionality reduction;25 a sig-
nificant multi-locus effect among NQO1, MPO, and CAT was
reported on asthma using a focused interaction testing
framework.26 Although IgAN is also gradually considered to
be a common complex disease, studies on multi-factorial
analysis have not been reported yet.
In this study, we investigated the interactive effect of two
glycosyltransferase genes, C1GALT1 and ST6GALNAC2, on
IgAN, using two independent methods, FAMHAP 16 at first,
and later a novel divergence-based multi-locus algorithm
(DBMA) for further confirmation. Our results indicated that
variants in C1GALT1 and ST6GALNAC2 had a potential gen-
etic interactive effect, both in terms of predisposition and
severity of IgAN.
RESULTS
Evidence for haplotype–haplotype interaction
Susceptibility to IgAN. Haplotypes in the C1GALT1 gene
were divided into four groups: YATIG, YAGDA, and YATDG,
which were haplotypes that were earlier identified to be
associated with IgAN predisposition, and the last group was
named OTHERS, which included all the other unrelated
haplotypes in C1GALT1.22 In accordance with the same
classification criteria, we also divided haplotypes in the
ST6GALNAC2 gene into two groups: ADG (earlier identified
as an IgAN-associated haplotype in ST6GALNAC2) and
OTHERS (other not associated haplotypes in ST6GAL-
NAC2).23 Four haplotype groups in C1GALT1 and two in
ST6GALNAC2 result in eight groups of haplotype–haplotype
combinations. The frequency distribution of the eight
haplotype–haplotype combinations showed significant differ-
ence between IgAN patients and healthy controls (P-
value¼ 6.3028 107, obtained by 7-d.f. w2-test). The
haplotype–haplotype combinations bearing risky haplotypes
in both genes, or having a more severe risky haplotype in
C1GALT1, showed a higher OR value for genetic IgAN
predisposition than they did without them (Figure 1). These
results indicated that the haplotype–haplotype combinations
in C1GALT1 and ST6GALNAC2 were associated with genetic
susceptibility to IgAN.
Clinical manifestations and histological classifications. In
IgAN patients, according to OR value, which represented the
risk of genetic susceptibility to IgAN, we divided haploty-
pe–haplotype combinations in C1GALT1 and ST6GALNAC2
into several subgroups. For the consideration of keeping the
same OR interval among subgroups and for combining
haplotype–haplotype combinations with a near OR value into
the same subgroup, we divided them into four subgroups,
subgroups 1 to 4, representing an OR value of IgAN
predisposition less than 1, from 1 to 2, from 2 to 3, and
larger than 3, respectively. Subgroup 1 included two
haplotype–haplotype combinations: ATIG (C1GALT1)
* Others (ST6GALNAC2) (OR¼ 0.67) and ATIG
(C1GALT1) * ADG (ST6GALNAC2) (OR¼ 0.82); subgroup
2 included three haplotype–haplotype combinations: Others
(C1GALT1) * Others (ST6GALNAC2) (OR¼ 1.00), Others
(C1GALT1) * ADG (ST6GALNAC2) (OR¼ 1.47), and AGDA
(C1GALT1) * Others (ST6GALNAC2) (OR¼ 1.46); subgroup
3 included two haplotype–haplotype combinations: AGDA
(C1GALT1) * ADG (ST6GALNAC2) (OR¼ 2.13) and ATDG
(C1GALT1) * Others (ST6GALNAC2) (OR¼ 2.06); and
subgroup 4 included one haplotype–haplotype combination:
ATDG (C1GALT1) * ADG (ST6GALNAC2) (OR¼ 3.58).
Clinical manifestations at the time of renal biopsy and
histological classifications were compared among these
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Figure 1 | Haplotype–haplotype combinations in C1GALT1 and ST6GALNAC2 and their association with IgAN. The frequency
distribution was significantly different among eight haplotype–haplotype combinations in C1GALT1 and ST6GALNAC2 (P¼ 6.3 107)
(OR means the odds ratio for susceptibility to IgAN).
Kidney International (2009) 76, 190–198 191
L Zhu et al.: Genetic interactive effect on IgAN o r i g i n a l a r t i c l e
subgroups. The results showed that the proportion of
patients with estimated glomerular filtration rate (eGFR)
more than 90 ml/min gradually decreased from subgroup 1 to
4 while the OR value of the haplotype–haplotype combina-
tions to IgAN predisposition increased, whereas the other
comparisons on serum IgA level, 24 h urine protein excretion,
history of gross hematuria, and Haas grade showed no
significant difference (Table 1).
Evidence for multi-locus interaction
Susceptibility to IgAN. We applied the proposed non-
parametric DBMA approach to our case–control data in IgAN,
and the results are shown in Table 2. A 5-locus combination,
L1,4,5,6,8 (L1,4,5 in C1GALT1 and L6,8 in ST6GALNAC2),
was significantly associated with genetic susceptibility to
IgAN, with an experiment-wise P-value less than 105,
confirming the identified interactive effect in C1GALT1 and
ST6GALNAC2 on genetic IgAN predisposition by FAMHAP.
Among the five interacting loci, a sub-combination, L1,4,5,
also showed strong significance, consistent with our former
result that C1GALT1 itself mainly contributed to IgAN
predisposition.22
Clinical manifestation and histological classifications. In
patients with IgAN, the effect of single-nucleotide poly-
morphisms (SNPs) in C1GALT1 and ST6GALNAC2 on
clinical manifestations and histological classification was also
analyzed.
At first, comparisons among genotypes were carried out at
each single locus, but no association was found (Table 3). As
a 3-locus combination, L1,4,5 (all the three loci were in
C1GALT1), showed a strong association with IgAN predis-
position, we tested the effect of the 3-locus combination,
L1,4,5, in C1GALT1 on clinical manifestations and histolo-
gical classifications. According to the OR value, which
represented the risk of genetic susceptibility to IgAN, we
divided the combinatory genotypes of the three SNP loci
into different subgroups. We used two cutoff OR values to best
separate all the IgAN patients into three distinct subgroups: the
high-risk group, including genotypes the OR value of IgAN
predisposition of which was bigger than 2.6 and had more than
five individuals in the data set; the low-risk group, including
genotypes the OR of which was smaller than 0.7 and had more
than five individuals in the data set; the middle-risk group,
which included the rest of the genotypes. Nevertheless, no
significant association was found (Table 4).
Table 1 | Comparison of clinical manifestations and histological classifications among subgroups 1–4
Variables Subgroup 1a Subgroup 2b Subgroup 3c Subgroup 4d P-value
eGFR
Frequency (CKD 1) 0.100 0.819 0.067 0.014 0.0105
Frequency (CKD 2–5) 0.055 0.827 0.093 0.025
Frequency ratio (CKD 1/CKD 2–5) 1.833 0.990 0.719 0.569
Gross hematuria
Frequency (with) 0.085 0.808 0.086 0.021 0.3802
Frequency (without) 0.061 0.837 0.082 0.020
Frequency ratio (with/without) 1.398 0.965 1.042 1.077
Proteinuria
Frequency (41 g/day) 0.072 0.828 0.077 0.023 0.5712
Frequency (p1 g/day) 0.080 0.817 0.088 0.015
Frequency ratio (41/p1(g/day)) 0.890 1.014 0.871 1.586
Elevated serum IgA
Frequency (with) 0.089 0.820 0.075 0.161 0.6894
Frequency (without) 0.073 0.825 0.080 0.021
Frequency ratio (with/without) 1.226 0.993 0.930 0.752
Haas grade
Frequency (stage 1–2) 0.074 0.820 0.088 0.018 0.8338
Frequency (stage 3–5) 0.068 0.828 0.080 0.024
Frequency ratio (stage 1–2/stage 3–5) 1.082 0.991 1.098 0.763
eGFR, estimated glomerular filtration rate; IgAN, immunoglobulin A nephropathy; OR, odds ratio.
aSubgroup 1 included IgAN patients carrying haplotype–haplotype combinations in C1GALT1 and ST6GALNAC2 whose OR value for IgAN predisposition was o1.
bSubgroup 2 included IgAN patients carrying haplotype–haplotype combinations in C1GALT1 and ST6GALNAC2 whose OR value for IgAN predisposition ranged from 1 to 2.
cSubgroup 3 included IgAN patients carrying haplotype–haplotype combinations in C1GALT1 and ST6GALNAC2 whose OR value for IgAN predisposition ranged from 2 to 3.
dSubgroup 4 included IgAN patients carrying haplotype–haplotype combinations in C1GALT1 and ST6GALNAC2 whose OR value for IgAN predisposition was 43.
Table 2 | Association of multi-locus variants in C1GALT1 and
ST6GLANAC2 with IgAN analyzed by DBMA
Loci combination Consistency Average divergence P-value
L4 10 0.04035 0.036
L4,5 7 0.10053 0.294
L1,4,5 10 0.31283 o0.00001
L1,4,5,6 9 0.38024 0.069
L1,4,5,6,8 10 0.52011 o0.00001
L1,3,4,5,6,8 6 0.57553 0.280
L1,3,4,5,6,8,9 5 0.57776 0.389
L1,2,3,4,5,6,8,9 7 0.57458 0.287
DBMA, divergence-based multi-locus algorithm; IgAN, immunoglobulin A nephropathy.
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On the basis of the above-identified two gene 5-locus
L1,4,5,6,8 interaction on IgAN predisposition, we investi-
gated the interactive effect on clinical manifestations and
histological classifications. Similarly, we separated all the
IgAN patients into high-risk group, middle-risk group, and
low-risk group using the same two cutoff OR values
(Supplementary Material 1 lists all the genotype combina-
tions in each group). Age and gender distribution showed no
difference among the three groups. It was interesting to find
that eGFR level and 24 h urine protein excretion were
significantly different among the three groups (P-
value¼ 0.0005 for eGFR and P-value¼ 0.0477 for proteinur-
ia) (Table 5). When compared with the middle-risk group,
the high-risk group showed lower eGFR and higher
proteinuria, and the low-risk group showed higher eGFR
and lower proteinuria (Figure 2). No significant difference
was found in serum IgA level, 24 h urine protein excretion,
history of gross hematuria, and Haas grade (Table 5).
Renal survival analysis. One hundred and nineteen IgAN
patients with follow-up data were recruited for renal survival
analysis. Owing to the slow progression character of IgAN,
we combined the moderate-risk group and the mild-risk
group to cerate the non-high-risk group and compared it
with the high-risk group. Kaplan–Meier analysis showed that
the rate of patients who reached end-stage renal disease was
significantly higher in the high-risk group than that in the
non-high-risk group (P-value¼ 0.0220) (Figure 3).
Multi-locus interaction effect of variants in C1GALT1 and
ST6GALNAC2 on serum IgA1 glycosylation pattern
GalNAc is the core structure of O-glycan in IgA1 mole-
cules. It can be extended with galactose and sialic acid by
Table 3 | Comparison of clinical manifestations and histological classifications at single SNP sites
P-value
Clinical manifestations Haasa Gross hematuriaa eGFRb Proteinuriac Serum IgA levelc
L1 0.9738 0.0577 0.7990 0.6309 0.6541
L2 0.3478 0.6921 0.7890 0.6978 0.8975
L3 0.9668 0.7176 0.9977 0.7915 0.3819
L4 0.8678 0.1766 0.0827 0.7959 0.7706
L5 0.9400 0.4843 0.3017 0.8300 0.3980
L6 0.1072 0.8429 0.1829 0.1852 0.8817
L7 0.6774 0.6679 0.9010 0.1856 0.0709
L8 0.8295 0.7383 0.0964 0.3245 0.2849
L9 0.3362 0.8079 0.8797 0.4238 0.6695
aThe P-value here is obtained by the w2-test.
bThe P-value here is obtained by analysis of variance (ANOVA), in which F-test was performed.
cThe P-value here was obtained by ANOVA, in which the Kruskal–Wallis non-parametric test was performed.
Table 4 | Comparison of clinical manifestations and histological classifications among the high risk, middle risk, and low-risk
group based on L1,4,5 in C1GALT1
Variables High-risk group Middle-risk group Low-risk group P-value
Number 25 612 23
Age (year) 37.5±15.3 30.9±11. 3 28.6±9.3 0.0624a
Gender, % 0.1118b
Male 52.00 57.19 78.26
Female 48.00 42.81 21.74
eGFR (ml/min) mean±s.d. 80.4±41.6 84.5±33.5 81.3±41.6 0.7976c
Gross hematuria, % 0.1587b
With 36.00 41.18 21.74
Without 64.00 58.82 78.26
Proteinuria (g/day) mean±s.d. 2. 40±3.08 2.40±2.66 2.29±2.41 0.9119a
Serum IgA level (mg/ml) mean±s.d. 2.94±0.98 3.02±1.14 2.97±1.02 0.6568a
Hass grade, %
1 32.00 40.93 31.82 0.1509b
2 16.00 6.99 13.64
3 28.00 35.44 27.27
4 12.00 8.82 4.55
5 12.00 7.82 22.73
ANOVA, analysis of variance; eGFR, estimated glomerular filtration rate; IgAN, immunoglobulin A nephropathy.
aThe P-value here was obtained by ANOVA, in which the Kruskal–Wallis non-parametric test was performed.
bThe P value here was obtained by the w2-test.
cThe P value here was obtained by ANOVA, in which F-test was performed.
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b-1,3-galactosyltransferase (encoding product of C1GALT1) and
a-2,6-sialyltransferase (encoding product of ST6GALNAC2).
Without b-1,3-galactosyltransferase and a-2,6-sialyltransferase,
O-glycan would seem to have only the core GalNAc, which we
call GalNAc exposure, and can be detected by HAA lectin.
To evaluate the correlation between variants in the two key
glycosylation-associated genes (genotype) and the glycosylation
pattern of serum IgA1 (phenotype), we measured the GalNAc
exposure of serum IgA1, which represents the combinational
glycosyltransferase effect of b-1,3-galactosyltransferase and
a-2,6-sialyltransferase. Patients with IgAN in the high-risk
group showed significantly elevated GalNAc exposure of serum
IgA1 than those in the low-risk group (0.1405 vs 0.1787,
P-value¼ 0.035) (Figure 4).
DISCUSSION
For the polygenic character of IgAN and for the functional
importance of aberrant glycosylated IgA1 in IgAN,12,27 in this
study, we chose two key glycosyltransferase genes, C1GALT1
and ST6GALNAC2, to explore the genetic interactive effect
on IgAN.
First, we found that variants in C1GALT1 and ST6GAL-
NAC2 interacted to influence susceptibility to IgAN. Our
results herein were not only consistent with our earlier two
genetic studies, which implied the involvement of the two
genes in IgAN predisposition, but were also significant for its
first-time identification of a genetic interactive effect on
IgAN predisposition. Second, we further showed that genetic
interactive effect is associated with IgAN severity. As
glycosylation of IgA1 was reported to be correlated with
prognosis in IgAN patients,16 we additionally explored the
effect of genetic variation on traits of IgAN. Although single
SNP in a single gene showed no correlation, variant
combinations in C1GALT1 and ST6GALNAC2, grouped
according to the risk of IgAN predisposition, were associated
with at least eGFR level and probably proteinuria, which were
two well-approved risk factors for poor long-term renal
outcome in IgAN patients28–30 Furthermore, the significant
different cumulative renal survival rate provided strong
support to the contribution of a genetic interactive effect in
Table 5 | Comparison of clinical manifestations and histological classifications among the high risk, middle risk, and low-risk
group based on L1,4,5,6,8 in C1GALT1 and ST6GLANAC2
Variables High-risk group Middle-risk group Low-risk group P-value
Number 84 491 85
Age (year) 32.1±13.9 31.2±11.1 29.40±11.0 0.3017a
Gender, % 0.1857b
Male 60.7 55.8 65.9
Female 39.3 44.2 34.1
eGFR (ml/min) mean±s.d. 71.6±35.6 84.5±32.7 94.3±37.2 0.0005c
Gross hematuria, % 0.8776b
With 42.86 39.92 40.00
Without 57.14 60.08 60.00
Proteinuria (g/day) mean±s.d. 2.93±3.36 2.10±2.48 2.14±2.83 0.0477a
Serum IgA level (mg/ml) mean±s.d. 3.12±1.19 3.00±1.05 2.97±1.44 0.8660a
Hass grade, % 0.4502b
1 36.90 40.33 43.37
2 7.14 7.07 10.84
3 34.52 35.34 32.53
4 8.33 9.77 3.61
5 13.10 7.48 9.64
ANOVA, analysis of variance; eGFR, estimated glomerular filtration rate; IgAN, immunoglobulin A nephropathy.
aThe P-value here was obtained by ANOVA, in which the Kruskal–Wallis non-parametric test was performed.
bThe P-value here was obtained by the w2-test.
cThe P-value here was obtained by ANOVA, in which F-test was performed.
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Figure 2 | Box plot of the distributions of eGFR and
proteinuria in the high-risk group, middle-risk group, and
low-risk group. The genotypes of L1,4,5,6,8 are divided into three
groups: the high-risk group (n¼ 84) includes the genotypes the
OR of which is bigger than 2.6 and have more than five individuals
in the data set; low-risk group (n¼ 85) includes genotypes the OR
of which is smaller than 0.7 and have more than five individuals in
the data set; the rest are in the middle-risk group (n¼ 491).
Compared with the middle-risk group, the high-risk group
showed lower eGFR and higher proteinuria, whereas the low-risk
group showed higher eGFR and lower proteinuria (P-value for
eGFR: 0.0005, P-value for proteinuria: 0.0477).
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C1GALT1 and ST6GALNAC2 on long-term renal outcome.
Third, we proved the correlation between the genotypes and
phenotypes of the two glycosyltransferase genes; in this case
in different variant combinations in C1GALT1 and ST6GAL-
NAC2, which showed significantly different glycosylation
patterns in IgA1. Taken together, we found that variants in
C1GALT1 and ST6GALNAC2, through their interaction on
the glycosylation pattern of IgA1, at last showed their
interaction both on predisposition and severity of IgAN.
After lots of studies on the aberrant glycosylated IgA1 in
IgAN, our genetic findings reinforced the importance of
O-glycosylation in IgAN pathogenesis. C1GALT1 and
ST6GALNAC2 were the coding genes for the two key
glycosyltransferases in IgA1 O-glycosylation process,
b1,3-galactosyltransferase and a2,6-sialyltransferase, which
mediate the addition of galactose and sialic acid onto GalNAc
residues of IgA1, respectively. As illustrated in Figure 5, we
speculated the potential mechanism of our identified genetic
interactive effect on IgAN. As all the SNP sites we tested were
in non-coding regions, they are unlikely to induce a protein
structure change, but may influence an expression of
these two genes and finally change the total profile of
b1,3-galactosyltransferase and a2,6-sialyltransferase activities
in B lymphocytes. On account of both b1,3-galactosyltrans-
ferase and a2,6-sialyltransferase catalyzing monosaccharide
onto the same substrate, GalNAc, the possible functional
interaction between them during the IgA1 molecule O-
glycosylation process, because of substrate competition,
should be seriously considered, although no experimental
evidence has been obtained as yet. The integrated effects of
different profiles of b1,3-galactosyltransferase and a2,6-
sialyltransferase activities, as well as their complicated
functional interactions, lead to different glycosylation
patterns of O-glycan in IgA1. A number of studies have
proven the influence of aberrant glycosylated IgA1 on
glomerular deposition 31,32 and injury to renal intrinsic
cells.19–21 Therefore, different glycosylated IgA1 presented, on
one hand, deposition distinction in mesangium, which
associated with IgAN predisposition, and, on the other hand,
diversity in renal injury, which correlated with IgAN severity.
Undoubtedly, as a multi-factorial and polygenic complex
disease, many genes and environmental factors contributed
to the occurrence and progression of IgAN. We just proposed
the interactive effect of variants in C1GALT1 and ST6GAL-
NAC2 to be one of the causal mechanisms that could be
responsible for IgAN predisposition and IgAN severity.
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Figure 4 | Comparison of GalNAc exposure in serum IgA1
molecules in IgAN patients in the high-risk group and low-risk
group. Patients in the high-risk group (n ¼ 74) presented a higher
level of GalNAc exposure in serum IgA1 molecules than those in
the low-risk group (n¼ 65) (0.1405 vs 0.1787, P-value¼ 0.035).
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Figure 5 | Illustration of the potential mechanism of the
interactive effect of variants in C1GALT1 and ST6GALNAC2 on
IgAN. Variants in C1GALT1 and ST6GALNAC2 might interact to
influence the expression of b1,3-galactosyltransferase and a2,6-
sialyltransferase and result in the different profiles of
glycosyltransferase activities through an unknown mechanism.
Meanwhile, the two glycosyltransferases might present a
functional interaction effect, together with the different profiles of
glycosyltransferase activities, to induce the synthesis of different
glycosylated IgA1 molecules. Thereafter, different glycosylated
IgA1 molecules mediate the IgAN predisposition and IgAN
severity through their different capacities for meangial area
deposition and renal intrinsic cells injury. Solid line arrow denotes
mechanisms shown by earlier or present studies. Dashed line
arrow denotes speculated mechanisms.
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Figure 3 | Kaplan–Meier renal survival curves of IgAN patients
in the high-risk group and the non-high-risk group. In the
high-risk group (OR value42.6, n¼ 15), the cumulative renal
survival was 73.33% at 1 year and 66.67% at 8 years; in the non-
high-risk group (OR value o2.6, n¼ 104), the cumulative renal
survival was 96.15% at 1 year and 81.40% at 8 years. P-
value¼ 0.0220.
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Meanwhile, we used two independent methods to explore
the potential interactive effect of C1GALT1 and ST6GAL-
NAC2 in two ways, and obtained similar results. One is the
earlier reported software, FAMHAP,33 for haplotype–haplo-
type interaction, and the other is a novel DBMA approach for
SNP–SNP interaction. Systematic simulation studies illu-
strated that DBMA not only outperformed multifactor-
dimensionality reduction in epistasis mapping, but also did
not lose much power in detecting marginal effect (Supple-
mentary Material 2). The advantages of DBMA are mainly in
relation to two aspects. First, divergence as a score statistic
estimates both absolute differences and relative differences, as
illustrated in its definition. This is more robust in detecting
different kinds of effects of disease susceptibility loci with
different minor allele frequencies. Second, taking advantage
of a well-designed re-sampling strategy to get ‘consistency’
for each locus combination, DBMA could get more robust
results than by using divergence only. Simulation results
suggest that the proposed DBMA method is suitable for
detecting the joint effect of multiple loci, which is urgently
required in analyzing the case–control data of common
complex diseases, as seen in this paper.
In conclusion, using two independent methods, FAMHAP
and DBMA, we explored the genetic interactive effect of
variants in glycosyltransferase genes, C1GALT1 and ST6GAL-
NAC2, on IgAN in a large Northern Chinese population. Our
results suggested for the first time that variants in C1GALT1
and ST6GALNAC2 had interaction on IgA1 O-glycosylation,
and on the genetic susceptibility, clinical variability, and
long-term outcome of IgAN, which implied that C1GALT1
and ST6GALNAC2 contributed to IgAN predisposition and
severity in a polygenic manner.
MATERIALS AND METHODS
Study population
The recruited population was the same as reported earlier (including
670 patients with renal biopsy-proved IgAN and 494 age-, gender-
and geographically matched healthy controls).22,23 As our study was
for genetic interactive effect, two IgAN patients and seven healthy
controls with missing genotype data were excluded, which left
behind 1155 individuals (including 668 patients with IgAN and 487
healthy controls).
Clinical and histological data of 660 patients with IgAN were
collected. Clinical manifestations at the time of renal biopsy,
including serum IgA level, serum creatinine level, 24 h urine protein
excretion, and history of gross hematuria, were collected from
clinical records. The eGFR was calculated by the Modified
Glomerular Filtration Rate Estimating Equation for the Chinese
population.34 Haas pathological classification was assessed in IgAN
patients whose renal biopsy tissues contained more than 10
glomeruli.35 One hundred and nineteen patients with IgAN were
followed up for 61.87±23.45 months. Renal survival duration was
defined as points from renal biopsy to end-stage renal disease.
The protocol for this study was approved by the Medical Ethics
Committee of Peking University, and informed written consent for
the genetic studies was obtained from every participant.
SNP sites and genotyping
In our earlier studies, we screened SNPs in C1GALT1 and
ST6GALNAC2, and found nine SNPs in C1GALT1 and ten in
ST6GALNAC2. Using htSNPer1.0 software, five SNPs in C1GALT1
(-796C4T, -527A4G, -392G4T, -354C4-, and *211G4A)22 and
four in ST6GALNAC2 (-988A4G, -449_-450insCGGC, -135C4G,
and 186þ 12G4A)23 were selected as tagging SNPs to represent the
variants in the two genes. In this study, we chose all the nine tagging
SNP sites to explore the genetic interactive effect of the two genes
(Table 6). Genotyping of the nine SNPs was described in detail in
our earlier paper.22,23
Haplotype–haplotype interaction analysis
We used FAMHAP1633 to detect the haplotype–haplotype interac-
tion between C1GALT1 and ST6GALNAC2. FAMHAP 16 is the
software for haplotype-based association analysis, which uses the
expectation-maximization algorithm to obtain maximum-likeli-
hood estimates of the haplotype frequencies. At first, association
between haplotype–haplotype combinations and IgAN predisposi-
tion was evaluated in the total recruited population. Second, in
patients with IgAN, clinical manifestations, and histological
classifications were compared among subgroups based on haploty-
pe–haplotype combinations.
Multi-locus interaction analysis
For further confirmation, we proposed a DBMA method for analyzing
the interaction of multiple loci in C1GALT1 and ST6GALNAC2 on
IgAN status as well as on IgAN traits.
The DBMA was developed on the basis of Sun’s36 work in which
divergence was first introduced into association studies. The
Table 6 | Polymorphisms in C1GALT1 and ST6GLANAC2
Gene name Locus name dbSNP name Region Positiona Allelesb
C1GALT1 Locus 1 rs9639031 50flankingc 796 C4T
Locus 2 novel 50flanking 527 A4G
Locus 3 rs1008898 50flanking 392 G4T
Locus 4 rs5882115 50flanking 354 C4—
Locus 5 rs1047763 30UTR *211 G4A
ST6GALNAC2 Locus 6 novel 50flanking 988 G4A
Locus 7 rs3840858 50flanking 449,450 D4I (CGGC)
Locus 8 rs1867561 50flanking 135 G4C
Locus 9 rs2304921 Intron2 183+12 G4A
aThe base immediately preceding the start of translation is numbered as –1.
bWith major allele given first and minor allele given second.
c50flanking means upstream from the first transcribed nucleotide.
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definition of divergence was described in the following formula (1):
JD ¼
X
x
½pðxjDÞ  pðxjUÞ
 ln pðxjDÞ
pðxjUÞ ð1Þ;
where x represented a genotype of a given locus combination, and
p(x|D) and p(x|U) represented the probability of this genotype
in the affected and unaffected populations, respectively. Notice that
JD was non-negative definite. Under the null hypothesis that the
locus combination was unassociated with disease susceptibility,
we had p(x|D)¼ p(x|U) for all genotypes of the given locus
combination. In this case, JD would be zero. Otherwise, JD would
be non-zero. We used JD as the score statistic to test the null
hypothesis that a given locus combination was unassociated with
disease susceptibility.
We defined consistency to improve the robustness of the method.
Given a data set, 9/10 individuals were randomly sampled from each
case and control group, respectively. These subjects were pooled into
a new data set in which we calculated divergence for each n-locus
combination. Here, n¼ 1, y, N, with N being the biggest
combination size we were interested in, and/or was feasible for
computation. The biggest divergence and the responding locus
combination were recorded for combination size n. To reduce the
probability that the biggest divergence was caused by chance, the
sampling procedure was repeated 10 times. The number of times an
n-locus combination was verified as the one with the biggest
divergence among all the n-locus combinations in all the 10 re-
sampled data sets was defined as the consistency of this certain n-locus
combination. For n¼ 1, y, N, we reported the n-locus combination
with the biggest consistency as a candidate for association with disease
susceptibility. When there was more than one locus combination with
the biggest consistency, we reported the one with the biggest
divergence. The effect of a similar statistic, which was also named
‘consistency’ by multifactor-dimensionality reduction, has been
illustrated in improving the robustness of the algorithm 25.
We used permutation testing to derive the statistical significance for
each n-locus combination. A total of 1000 data sets were generated
from the original data set by randomly assigning labels (patients or
controls) for the individuals, without changing the percentage of
patients in the whole data set. The significant level of a given locus
combination was calculated as the proportion of permutated data sets
in which there was at least one n-locus combination that had a bigger
consistency, or had an equal consistency value but a bigger divergence
value. The P-value obtained by permutation testing less than 0.05 was
considered statistically significant.
Detection of GalNAc exposure on serum IgA1
Two extremities of patients with IgAN in the high-risk group (74
patients) and low-risk group (65 patients) were selected to detect
GalNAc exposure on serum IgA1 by ELISA, almost similar as that
reported by Moldoveanu et al.,37 with minor revision.
Contrary to Moldoveanu, who aimed at detecting Gal-deficient
IgA1, our purpose was to measure the GalNAc exposure of IgA1.
Hence, neuraminidase treatments were not used. GalNAc exposure
of IgA1 was accessed for binding to biotin-labeled GalNAc-specific
lectin HAA (Sigma, St Louis, MO, USA), which specifically binds to
terminal GalNAc without Gal or Sialic acid.
Blocking solution and one serum sample bearing a high level of
GalNAc exposure, identified in our preliminary experiment, were
used as blank and positive controls, respectively. For standardiza-
tion, each plate contained a blank control and the same positive
control. The absorbance value of the blank control was regarded as
0, whereas that of the positive control was 100%. Therefore, we
expressed the level of GalNAc exposure in each sample as the relative
absorbance value.
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